InsiderTrades

Form 4 for DRMA Dermata Therapeutics, Inc.

Accepted 2021-08-17 00:00:00 ET · period of report 2021-08-17 · accession 0000905718-21-001108 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2021-08-17 2021-08-17 DRMA Proehl Investment Ventures LLC 10% C - Cnv Deriv — +1.99M 1.57M New —
DM 2021-08-17 2021-08-17 DRMA Proehl Investment Ventures LLC 10% C - Cnv Deriv $0.00 -36.34M 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-08-17 C A 361,147 — 1,278,464 D — — (F1) The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
2 Common Common Stock 2021-08-17 C A 111,951 — 1,390,415 D — — (F2) The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.
3 Common Common Stock 2021-08-17 C A 85,640 — 2,905,544 D — — (F5) The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.
4 Common Common Stock 2021-08-17 C A 1,247,904 — 2,819,904 D — — (F4) The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.
5 Common Common Stock 2021-08-17 C A 181,585 — 1,572,000 D — — (F3) The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.
6 Derivative Series 1b Preferred Stock 2021-08-17 C D 3,722,500 $0.00 0 D — · — to — 181,585 Common Stock (F3) The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.
7 Derivative Series 1d Preferred Stock 2021-08-17 C D 2,436,657 $0.00 0 D — · — to — 361,147 Common Stock (F1) The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
8 Derivative Series 1a Preferred Stock 2021-08-17 C D 2,295,000 $0.00 0 D — · — to — 111,951 Common Stock (F2) The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.
9 Derivative Warrant to Purchase Common Stock 2021-08-17 C A 27,987 $0.00 27,987 D $20.50 · 2016-11-15 to 2026-03-14 27,987 Common Stock
10 Derivative Series 1c Preferred Stock 2021-08-17 C D 25,582,050 $0.00 0 D — · — to — 1,247,904 Common Stock (F4) The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.
11 Derivative Series 1 Preferred Stock 2021-08-17 C D 1,755,622 $0.00 0 D — · — to — 85,640 Common Stock (F5) The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.
12 Derivative Series 1a Warrants 2021-08-17 C D 573,750 $0.00 0 D — · 2016-11-15 to 2026-03-14 27,987 Common Stock (F6) The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO.